ClinicalTrials.gg

Program

ezabenlimab

Also written as “Ezabenlimab” and “BI 754091”.

In Boehringer Ingelheim's pipeline, PD-1 antibody. Its studies are mostly in Neoplasms · Small Cell Lung Carcinoma · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms, led by Boehringer Ingelheim.

Furthest: phase 3, since Apr 15, 202413 company-led studies, 2 open or runningNext primary completion: Mar 8, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim132 open or runningphase 3since Apr 15, 2024Oct 31, 2016Mar 8, 2027phase 1 · NCT05846516
  • Named in Boehringer Ingelheim’s own pipeline as Ezabenlimab, phase 1, as of Aug 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 31, 2016First study: phase 1 study in NeoplasmsFirst studyNCT02952248 · 110 enrolled · United States, Canada, United Kingdom
  2. May 23, 2017Phase 1 study in NeoplasmsNCT03166631 · 62 enrolled · United States
  3. Feb 9, 2018Early phase 1 study in NeoplasmsNCT03433898 · 146 enrolled · Japan, South Korea, Taiwan
  4. Nov 26, 2018Phase 1 study in Carcinoma, Non-Small-Cell LungNCT03780725 · 8 enrolled · Netherlands
  5. May 24, 2019Phase 1 study in NeoplasmsNCT03964233 · 119 enrolled · United States, Australia, Belgium and more
  6. Oct 30, 2019Phase 1 study in NeoplasmsNCT04147234 · 42 enrolled · United States, Spain, United Kingdom
  7. Aug 3, 2020Phase 2 study in Anal Canal Squamous Cell CarcinomaNCT04499352 · Korea, Republic of
  8. Nov 27, 2020Phase 1 study in Solid TumorsNCT04653142 · 18 enrolled · Japan
  9. Feb 10, 2022Phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT05249426 · 48 enrolled · United States, France, Japan and more
  10. Jul 1, 2022Phase 1 study in Colorectal NeoplasmsNCT05446129 · 2 enrolled · United States
  11. Apr 18, 2023Phase 1 study in Pancreatic Ductal AdenocarcinomaNCT05846516 · 59 enrolled · United States, Germany, Spain and more
  12. May 25, 2023Phase 1 study in Small Cell Lung CarcinomaNCT05879978 · 45 enrolled · Belgium, France, Germany and more
  13. Apr 15, 2024Phase 3 study in Histiocytoma, Malignant FibrousNCT06370871

Ahead

  1. Mar 8, 2027Primary completion: phase 1 study in Pancreatic Ductal AdenocarcinomaNCT05846516

TargetBeta

“PD-1 antibody”the company's pipeline, read by Claude · source

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34
sasanlimabPfizerphase 34

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06370871Histiocytoma, Malignant Fibrous3WithdrawnJul 3, 20260
NCT05879978Small Cell Lung Carcinoma · Belgium, France, Germany and more1Active, not recruitingJun 11, 202545
NCT05846516Pancreatic Ductal Adenocarcinoma · United States, Germany, Spain and more1Active, not recruitingMar 8, 202759
NCT05446129Colorectal Neoplasms · United States1TerminatedAug 11, 20232
NCT05249426Squamous Cell Carcinoma of Head and Neck · United States, France, Japan and more1CompletedJul 15, 202448
NCT04653142Solid Tumors · Japan1CompletedApr 20, 202218
NCT04499352Anal Canal Squamous Cell Carcinoma · Korea, Republic of2WithdrawnOct 19, 20200
NCT04147234Neoplasms · United States, Spain, United Kingdom1CompletedNov 15, 202242
NCT03964233Neoplasms · United States, Australia, Belgium and more1CompletedSep 5, 2024119
NCT03780725Carcinoma, Non-Small-Cell Lung · Netherlands1TerminatedFeb 19, 20208
NCT03433898Neoplasms · Japan, South Korea, TaiwanEarly 1CompletedJul 20, 2023146
NCT03166631Neoplasms · United States1TerminatedSep 15, 202062
NCT02952248Neoplasms · United States, Canada, United Kingdom1CompletedApr 30, 2021110

How it is read

Names in the registry

  • “Ezabenlimab”, 6 entries
  • “BI 754091”, 6 entries
  • “ezabenlimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.